OCULAR THERAPEUTIX (OCUL) stock: insider trades, news & valuation
Net sellingShare price and insider trades
OCULAR THERAPEUTIX insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $461K and 8 sold $3.3M of OCUL stock on the open market.
Get emailed when insiders cluster-buy stocks like OCUL
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
OCUL insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $147K | 2 |
| Q3 2026 | — | 0 | $333K | 5 |
| Q2 2026 | — | 0 | $360K | 5 |
| Q1 2026 | $461K | 1 | $1.8M | 11 |
| Q4 2025 | — | 0 | $973K | 8 |
Valuation, profit and volume
Summary
Over the past 12 months, 1 OCULAR THERAPEUTIX, INC insider reported open-market purchases totaling $461K, while 8 insiders reported sales totaling $3.3M. 27 of 31 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 6SEC | Jeffrey S. HeierChief Scientific Officer | Sell Plan | 10,869307,457 held (−3%) | $7.05 | $77K | +7.0% | — |
| Oct 6SEC | Peter KaiserChief Development Officer | Sell Plan | 9,990254,388 held (−4%) | $7.05 | $70K | +7.0% | — |
| Sep 2SEC | Donald NotmanCOO | Sell | 1,099366,529 held (−0%) | $10.24 | $11K | -26.4% | — |
| Aug 26SEC | Pravin DugelSee Remarks | Sell Plan | 21,6492,525,429 held (−1%) | $10.77 | $233K | -30.0% | — |
| Aug 26SEC | Jeffrey S. HeierChief Scientific Officer | Sell Plan | 3,296318,326 held (−1%) | $10.78 | $36K | -30.1% | — |
| Aug 26SEC | Peter KaiserChief Development Officer | Sell Plan | 3,035264,378 held (−1%) | $10.77 | $33K | -30.0% | — |
| Aug 26SEC | Sanjay NayakChief Strategy Officer | Sell Plan | 1,897326,898 held (−1%) | $10.78 | $20K | -30.1% | — |
| Jun 5SEC | Nadia WaheedChief Medical Officer | Sell Plan | 14,828300,079 held (−5%) | $8.27 | $123K | -8.8% | — |
| May 28SEC | Pravin DugelSee Remarks | Sell Plan | 21,1562,597,170 held (−1%) | $8.20 | $173K | -8.0% | — |
| May 28SEC | Jeffrey S. HeierChief Scientific Officer | Sell Plan | 3,018320,350 held (−1%) | $8.20 | $25K | -8.0% | — |
| May 28SEC | Peter KaiserChief Development Officer | Sell Plan | 2,967266,141 held (−1%) | $8.20 | $24K | -8.0% | — |
| May 28SEC | Sanjay NayakChief Strategy Officer | Sell Plan | 1,858328,795 held (−1%) | $8.20 | $15K | -8.0% | — |
| Feb 25SEC | Pravin DugelSee Remarks | Sell Plan | 20,0563,013,022 held (−1%) | $8.28 | $166K | -8.9% | — |
| Feb 25SEC | Jeffrey S. HeierChief Scientific Officer | Sell Plan | 3,057323,368 held (−1%) | $8.28 | $25K | -8.9% | — |
| Feb 25SEC | Peter KaiserChief Development Officer | Sell Plan | 2,810269,108 held (−1%) | $8.28 | $23K | -8.9% | — |
| Feb 25SEC | Sanjay NayakChief Strategy Officer | Sell Plan | 1,759330,653 held (−1%) | $8.28 | $15K | -8.9% | — |
| Feb 24SEC | Richard L Md LindstromDirector | Buy | 60,229246,933 held (+32%) | $7.66 | $461K | -1.6% | — |
| Feb 24SEC | Nadia WaheedChief Medical Officer | Sell Plan | 3,510314,907 held (−1%) | $7.74 | $27K | -2.6% | — |
| Feb 17SEC | Pravin DugelSee Remarks | Sell Plan | 124,8823,033,078 held (−4%) | $9.04 | $1.1M | -16.6% | — |
| Feb 17SEC | Donald NotmanCOO | Sell | 11,446366,356 held (−3%) | $9.04 | $103K | -16.6% | — |
| Feb 17SEC | Sanjay NayakChief Strategy Officer | Sell Plan | 10,348332,412 held (−3%) | $9.04 | $94K | -16.6% | — |
| Feb 17SEC | Nadia WaheedChief Medical Officer | Sell Plan | 7,863318,417 held (−2%) | $9.04 | $71K | -16.6% | — |
| Feb 4SEC | Donald NotmanCOO | Sell | 6,035377,802 held (−2%) | $8.54 | $52K | -11.7% | — |
| Feb 4SEC | Donald NotmanCOO | Sell | 5,455383,837 held (−1%) | $9.14 | $50K | -17.5% | — |
| Nov 26SEC | Pravin DugelSee Remarks | Sell Plan | 19,5303,157,960 held (−1%) | $12.04 | $235K | -37.4% | — |
| Nov 26SEC | Jeffrey S. HeierChief Scientific Officer | Sell Plan | 3,469245,940 held (−1%) | $12.04 | $42K | -37.4% | — |
| Nov 26SEC | Peter KaiserChief Development Officer | Sell Plan | 3,007191,433 held (−2%) | $12.02 | $36K | -37.3% | — |
| Nov 26SEC | Sanjay NayakChief Strategy Officer | Sell Plan | 1,878277,860 held (−1%) | $12.04 | $23K | -37.4% | — |
| Nov 7SEC | Namrata SarojChief Business Officer | Sell Plan | 25,865174,135 held (−13%) | $10.74 | $278K | -29.8% | — |
| Oct 10SEC | Todd AndermanGeneral Counsel | Sell Plan | 11,13287,568 held (−11%) | $12.34 | $137K | -38.9% | — |
| Oct 6SEC | Jeffrey S. HeierChief Scientific Officer | Sell Plan | 10,502249,409 held (−4%) | $11.04 | $116K | -31.7% | — |
| Oct 6SEC | Peter KaiserChief Development Officer | Sell Plan | 9,653194,440 held (−5%) | $11.03 | $106K | -31.6% | — |
Insiders at OCULAR THERAPEUTIX, INC
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Pravin DugelSee Remarks | — | $1.9M | Aug 26, 2026 | — |
| Richard L Md LindstromDirector | $461K | — | Feb 24, 2026 | — |
| Jeffrey S. HeierChief Scientific Officer | — | $320K | Oct 6, 2026 | — |
| Peter KaiserChief Development Officer | — | $293K | Oct 6, 2026 | — |
| Namrata SarojChief Business Officer | — | $278K | Nov 7, 2025 | — |
| Nadia WaheedChief Medical Officer | — | $221K | Jun 5, 2026 | — |
| Donald NotmanCOO | — | $216K | Sep 2, 2026 | — |
| Sanjay NayakChief Strategy Officer | — | $166K | Aug 26, 2026 | — |
| Todd AndermanGeneral Counsel | — | $137K | Oct 10, 2025 | — |
OCUL stock: common questions
Are OCULAR THERAPEUTIX, INC insiders buying OCUL stock?
In the past 12 months, 1 insiders reported open-market purchases of OCUL worth $461K. The latest was Director Richard L Md Lindstrom bought $461K of OCUL at $7.66 — first open-market purchase in our records; raises the stake by 32%.
Are OCULAR THERAPEUTIX, INC insiders selling OCUL stock?
8 insiders reported sales worth $3.3M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is OCUL's 52-week range?
Over the past year OCUL has traded between $6.88 and $16.11. It last closed at $7.54 on Oct 9, 2026.